Denileukin diftitox

Denileukin diftitox
Denileukin diftitox
Systematic (IUPAC) name
Diphtheria toxin-Interleukin-2 fusion protein
Clinical data
AHFS/Drugs.com monograph
MedlinePlus a611024
Pregnancy cat. C(US)
Legal status ℞-only (US)
Pharmacokinetic data
Half-life 70-80 min
Identifiers
CAS number 173146-27-5 N
ATC code L01XX29
DrugBank BTD00084
UNII 25E79B5CTM N
ChEMBL CHEMBL1201550 N
Chemical data
Formula C2560H4042N678O799S17 
Mol. mass 57647.3 g/mol
 N(what is this?)  diftitox (verify)

Denileukin diftitox (trade name Ontak) is an antineoplastic agent, an engineered protein combining Interleukin-2 and Diphtheria toxin. This can bind to Interleukin-2 receptors[1] and introduce the diphtheria toxin into cells that express those receptors, killing the cells. In some Leukemias and Lymphomas malignant cells express these receptors, so denileukin diftitox can target these.

In 1999 Ontak was approved by the U.S. Food and Drug Administration (FDA) for treatment of Cutaneous T-cell lymphoma (CTCL).[2]

A recent study at the University of Louisville found the drug caused many stage IV cutaneous T-cell lympomas to regress or stabilize extending patient life expectancy from about eight months to more than a year; a clinically significant increase especially given the guarded prognosis of patients with advanced disseminated cutaneous T-cell lymphoma (CTCL) and the generally poor response to other available treatments.

There is some evidence tying it to vision loss.[3]

References

  1. ^ Turturro F (2007). "Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders". Expert Rev Anticancer Ther 7 (1): 11–7. doi:10.1586/14737140.7.1.11. PMID 17187516. 
  2. ^ http://www.pslgroup.com/dg/e1e1e.htm
  3. ^ Park M, Liu GT, Piltz-Seymour J, et al. (2007). "Vision loss following denileukin diftitox treatment: a case report of possible posterior ischemic optic neuropathy". Leuk. Lymphoma 48 (4): 808–11. doi:10.1080/10428190701268783. PMID 17454642. 

External links

v · d · eTargeted therapy / extracellular chemotherapeutic agents/antineoplastic agents (L01)
CI monoclonal antibodies ("-mab")
Others for solid tumors
Tyrosine-kinase inhibitors ("-nib")

ErbB: HER1/EGFR (Erlotinib, Gefitinib, Vandetanib) • HER1/EGFR and HER2/neu (Afatinib, Lapatinib, Neratinib)

RTK class III: C-kit and PDGFR (Axitinib, Pazopanib, Sunitinib, Sorafenib, Toceranib) • FLT3 (Lestaurtinib)

VEGFR (Axitinib, Cediranib, Pazopanib, Regorafenib, Semaxanib, Sorafenib, Sunitinib, Toceranib, Vandetanib)
Other
fusion protein against VEGF (Aflibercept) • proapoptotic peptide against ANXA2 and prohibitin (Adipotide) • exotoxin against IL-2 (Denileukin diftitox)

M: NEO

tsoc, mrkr

tumr, epon, para

drug (L1i/1e/V03)


Stub icon This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.